ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1,2,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
2,1,Metastases to central nervous system,Metastases to specified sites,Metastases,Neopl,N
3,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
4,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
4,2,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
5,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
6,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
6,2,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
7,1,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
7,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
7,3,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
8,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
8,2,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
9,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
10,1,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
10,2,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
10,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
10,4,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
11,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
12,1,Biliary sepsis,Hepatobiliary and spleen infections,Infections - pathogen unspecified,Infec,N
12,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
12,3,Hepatic failure,Hepatic failure and associated disorders,Hepatic and hepatobiliary disorders,Hepat,N
13,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
13,2,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
13,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
14,1,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
14,2,Triple negative breast cancer,Breast and nipple neoplasms malignant,Breast neoplasms malignant and unspecified (incl nipple),Neopl,N
15,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
15,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
16,1,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
17,1,Mean cell volume increased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
17,2,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
17,3,Obstruction,General signs and symptoms NEC,General system disorders NEC,Genrl,N
18,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
19,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
19,2,Metastases to heart,Metastases to specified sites,Metastases,Neopl,N
19,3,Neutrophil count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
19,4,Pulmonary thrombosis,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
19,5,White blood cell count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
20,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
20,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
21,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
22,1,Myelodysplastic syndrome,Myelodysplastic syndromes,Leukaemias,Neopl,Y
23,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
23,2,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
24,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
25,1,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
25,2,Glomerular filtration rate decreased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
25,3,Hepatic enzyme increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
26,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
27,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
27,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
27,3,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
27,4,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
28,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
29,1,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
29,2,Glomerular filtration rate decreased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
29,3,Hepatic enzyme increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
29,4,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
30,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
30,2,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
30,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
30,4,Eye swelling,Ocular disorders NEC,Eye disorders NEC,Eye,N
30,5,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
30,6,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
30,7,Headache,Headaches NEC,Headaches,Nerv,N
30,8,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
30,9,Neutrophil count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
30,10,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
30,11,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
30,12,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
30,13,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
30,14,White blood cell count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
31,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
31,2,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
31,3,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
31,4,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
31,5,Emotional disorder,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
31,6,Eye swelling,Ocular disorders NEC,Eye disorders NEC,Eye,N
31,7,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
31,8,Haemoglobin abnormal,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
31,9,Headache,Headaches NEC,Headaches,Nerv,N
31,10,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
31,11,Neutrophil count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
31,12,Platelet count abnormal,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
31,13,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
31,14,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
31,15,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
31,16,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
31,17,Taste disorder,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
32,1,Squamous cell carcinoma of the tongue,Lip and oral cavity neoplasms malignant,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
33,1,Myelodysplastic syndrome,Myelodysplastic syndromes,Leukaemias,Neopl,N
34,1,Tongue neoplasm malignant stage unspecified,Lip and oral cavity neoplasms malignant,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
35,1,Ear haemorrhage,Ear disorders NEC,Aural disorders NEC,Ear,N
35,2,Ear pain,Ear disorders NEC,Aural disorders NEC,Ear,N
35,3,Hypoacusis,Hearing losses,Hearing disorders,Ear,N
35,4,Tympanic membrane perforation,Tympanic membrane disorders (excl infections),Middle ear disorders (excl congenital),Ear,N
36,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
36,2,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
36,3,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
37,1,Metastatic neoplasm,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
38,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
38,2,Metastases to central nervous system,Metastases to specified sites,Metastases,Neopl,N
39,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
39,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
39,3,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
40,1,Carbohydrate antigen 125 increased,Cell marker analyses,Cytogenetic investigations and genetic analyses,Inv,N
40,2,Intentional product misuse,Intentional product misuses,Off label uses and intentional product misuses/use issues,Inj&P,N
41,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
41,2,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
41,3,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
41,4,Muscular weakness,Muscle weakness conditions,Muscle disorders,Musc,N
41,5,Musculoskeletal toxicity,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
41,6,Myalgia,Muscle pains,Muscle disorders,Musc,N
41,7,Myopathy,Myopathies,Muscle disorders,Musc,N
41,8,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
41,9,Rhabdomyolysis,Myopathies,Muscle disorders,Musc,N
42,1,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
42,2,Neoplasm recurrence,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
42,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
43,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
44,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
44,2,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
45,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
45,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
46,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
47,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
47,2,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
47,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
48,1,Acute pulmonary oedema,Pulmonary oedemas,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
49,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
50,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
51,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
52,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
52,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
53,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
53,2,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
53,3,COVID-19 pneumonia,Coronavirus infections,Viral infectious disorders,Infec,N
53,4,Leukopenia,Leukopenias NEC,White blood cell disorders,Blood,N
53,5,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
53,6,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
53,7,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
54,1,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
54,2,Hydronephrosis,Renal obstructive disorders,Renal disorders (excl nephropathies),Renal,N
54,3,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
55,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
55,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
55,3,Product use complaint,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
55,4,Throat irritation,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
56,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
57,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
58,1,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
59,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
59,2,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
60,1,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
60,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
60,3,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
60,4,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
60,5,Taste disorder,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
61,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
61,2,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
62,1,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
62,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
62,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
62,4,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
63,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
64,1,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
64,2,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
65,1,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
66,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
66,2,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
66,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
66,4,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
67,1,Papilloedema,Optic disc abnormalities NEC,"Ocular structural change, deposit and degeneration NEC",Eye,N
67,2,Visual brightness,Visual disorders NEC,Vision disorders,Eye,N
68,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
68,2,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
68,3,Cold sweat,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
68,4,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
68,5,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
68,6,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
68,7,Influenza like illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
68,8,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
68,9,Nipple pain,Breast signs and symptoms,Breast disorders,Repro,N
69,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
70,1,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
70,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
71,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
71,2,Eye pain,Ocular disorders NEC,Eye disorders NEC,Eye,N
71,3,Eye swelling,Ocular disorders NEC,Eye disorders NEC,Eye,N
71,4,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
71,5,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
71,6,Swelling of eyelid,"Lid, lash and lacrimal infections, irritations and inflammations","Ocular infections, irritations and inflammations",Eye,N
71,7,Swollen tongue,Tongue signs and symptoms,Tongue conditions,Gastr,N
71,8,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
72,1,Gamma-glutamyltransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
73,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
74,1,Bone pain,Bone related signs and symptoms,Bone disorders (excl congenital and fractures),Musc,N
74,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
75,1,Prostate cancer,Prostatic neoplasms malignant,Reproductive neoplasms male malignant and unspecified,Neopl,N
76,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
76,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
76,3,Metastases to bone marrow,Metastases to specified sites,Metastases,Neopl,N
76,4,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
77,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
78,1,Chest discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
78,2,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
78,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
79,1,SARS-CoV-2 test positive,Virus identification and serology,Microbiology and serology investigations,Inv,N
80,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
80,2,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
80,3,Bone pain,Bone related signs and symptoms,Bone disorders (excl congenital and fractures),Musc,N
81,1,Cardiac failure,Heart failures NEC,Heart failures,Card,N
81,2,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
81,3,Ovarian cancer recurrent,Ovarian neoplasms malignant (excl germ cell),Reproductive neoplasms female malignant and unspecified,Neopl,N
82,1,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
83,1,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
84,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
84,2,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
84,3,Prostatic specific antigen increased,Cell marker analyses,Cytogenetic investigations and genetic analyses,Inv,N
85,1,Transient ischaemic attack,Transient cerebrovascular events,Central nervous system vascular disorders,Nerv,N
86,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
86,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
87,1,Pulmonary mass,Respiratory tract disorders NEC,Respiratory disorders NEC,Resp,N
88,1,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
89,1,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
89,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
90,1,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
90,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
91,1,Suicidal ideation,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
92,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
93,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
94,1,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
94,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
94,3,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
94,4,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
95,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
95,2,Eye pruritus,"Ocular infections, inflammations and associated manifestations","Ocular infections, irritations and inflammations",Eye,N
95,3,Feeling hot,Feelings and sensations NEC,General system disorders NEC,Genrl,N
95,4,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
95,5,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
95,6,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
95,7,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
95,8,Skin tightness,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
95,9,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
95,10,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
96,1,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
96,2,Intentional product misuse,Intentional product misuses,Off label uses and intentional product misuses/use issues,Inj&P,N
97,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
97,2,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
98,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
98,2,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
98,3,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
98,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
98,5,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
98,6,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
99,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
100,1,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
101,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
102,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
102,2,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
103,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
104,1,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
104,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
104,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
104,4,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
104,5,Performance status decreased,General signs and symptoms NEC,General system disorders NEC,Genrl,N
105,1,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
105,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
105,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
105,4,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
105,5,Performance status decreased,General signs and symptoms NEC,General system disorders NEC,Genrl,N
106,1,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
107,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
108,1,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
108,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
108,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
109,1,Myelodysplastic syndrome,Myelodysplastic syndromes,Leukaemias,Neopl,N
110,1,Disease recurrence,General signs and symptoms NEC,General system disorders NEC,Genrl,N
110,2,Dyspepsia,Dyspeptic signs and symptoms,Gastrointestinal signs and symptoms,Gastr,N
110,3,Lymphadenopathy,Lymphatic system disorders NEC,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
110,4,Parotid gland enlargement,Salivary gland enlargements,Salivary gland conditions,Gastr,N
111,1,Adverse event,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
112,1,Hepatic necrosis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
113,1,Myelodysplastic syndrome,Myelodysplastic syndromes,Leukaemias,Neopl,N
114,1,Hepatitis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
115,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
116,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
116,2,Aspartate aminotransferase decreased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
116,3,Blood albumin abnormal,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
116,4,Blood alkaline phosphatase increased,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
116,5,Blood bilirubin abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
116,6,Blood creatine abnormal,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
116,7,Blood potassium abnormal,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
116,8,Blood sodium abnormal,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
116,9,Blood urea increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
116,10,Haemoglobin abnormal,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
116,11,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
116,12,White blood cell count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
117,1,Hepatic failure,Hepatic failure and associated disorders,Hepatic and hepatobiliary disorders,Hepat,N
118,1,Drug effect less than expected,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
118,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
119,1,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
119,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
120,1,Musculoskeletal stiffness,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
120,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
120,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
120,4,Quality of life decreased,Investigations NEC,"Investigations, imaging and histopathology procedures NEC",Inv,N
121,1,Brain injury,Structural brain disorders NEC,Structural brain disorders,Nerv,N
121,2,Metastases to central nervous system,Metastases to specified sites,Metastases,Neopl,N
122,1,Anger,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
122,2,Mood altered,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
123,1,Anger,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
123,2,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
123,3,Headache,Headaches NEC,Headaches,Nerv,N
123,4,Mood altered,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
124,1,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
125,1,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
125,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
126,1,Haemoglobin abnormal,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
126,2,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
126,3,Prostatic specific antigen increased,Cell marker analyses,Cytogenetic investigations and genetic analyses,Inv,N
126,4,White blood cell count abnormal,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
127,1,Metastases to central nervous system,Metastases to specified sites,Metastases,Neopl,N
128,1,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
129,1,Breast cancer metastatic,Breast and nipple neoplasms malignant,Breast neoplasms malignant and unspecified (incl nipple),Neopl,Y
129,2,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
129,3,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
129,4,Metastases to meninges,Metastases to specified sites,Metastases,Neopl,N
130,1,Ototoxicity,Ear disorders NEC,Aural disorders NEC,Ear,N
131,1,Ototoxicity,Ear disorders NEC,Aural disorders NEC,Ear,N
132,1,Breast cancer metastatic,Breast and nipple neoplasms malignant,Breast neoplasms malignant and unspecified (incl nipple),Neopl,Y
132,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
132,3,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
132,4,Metastases to meninges,Metastases to specified sites,Metastases,Neopl,N
133,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
134,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
135,1,Eczema,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
135,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
135,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
136,1,Cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
136,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
136,3,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
136,4,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
136,5,Stoma site extravasation,Stoma complications,Procedural related injuries and complications NEC,Inj&P,N
137,1,Acquired gene mutation,Gene mutations and other alterations NEC,"Chromosomal abnormalities, gene alterations and gene variants",Cong,N
138,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
138,2,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
139,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
139,2,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
140,1,Depression suicidal,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
141,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
142,1,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
142,2,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
142,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
142,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
142,5,Therapeutic product effect incomplete,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
143,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
143,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
144,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
144,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
144,3,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
145,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
146,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
146,2,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
147,1,Metastases to bone,Metastases to specified sites,Metastases,Neopl,N
148,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
149,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
149,2,Bone pain,Bone related signs and symptoms,Bone disorders (excl congenital and fractures),Musc,N
149,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
149,4,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
149,5,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
150,1,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
151,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
152,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
152,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
153,1,Urinary incontinence,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
154,1,Limb injury,Site specific injuries NEC,Injuries NEC,Inj&P,N
154,2,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
155,1,Urinary incontinence,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
156,1,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
156,2,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
157,1,Discontinued product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
157,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
158,1,Haematocrit decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
158,2,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
158,3,Red blood cell count decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
159,1,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
160,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
161,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
161,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
161,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
162,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
162,2,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
